SAB Biotherapeutics, Inc.
SABS
$3.70
-$0.05-1.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 20.70% | 37.72% | |||
| Gross Profit | -20.70% | -37.72% | |||
| SG&A Expenses | 9.17% | 9.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.90% | 26.81% | |||
| Operating Income | -16.90% | -26.81% | |||
| Income Before Tax | -19.20% | -11.91% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.20% | -11.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.20% | -11.91% | |||
| EBIT | -16.90% | -26.81% | |||
| EBITDA | -17.13% | -28.24% | |||
| EPS Basic | 19.95% | -494.10% | |||
| Normalized Basic EPS | 19.94% | -0.27% | |||
| EPS Diluted | 19.95% | -40.53% | |||
| Normalized Diluted EPS | 19.94% | -0.27% | |||
| Average Basic Shares Outstanding | 48.91% | 11.59% | |||
| Average Diluted Shares Outstanding | 48.91% | 11.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||